NCT06530511View on ClinicalTrials.gov

Polatuzumab, Rituximab and Orelabrutinib Combination Regimen (PRO) in the Treatment of Elderly Frail Patients with Treatment-naive Non-GCB DLBCL

PHASE2RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

August 1, 2024

Primary Completion Date

February 1, 2026

Study Completion Date

August 1, 2026

Conditions
Diffuse Large B Cell Lymphoma
Interventions
DRUG

Polatuzumab vedotin

Polatuzumab: 1.8 mg/kg, IV Drip infusion, D1;

DRUG

Rituximab

Rituximab: 375 mg/m2, IV Drip infusion, D1

DRUG

Orelabrutinib

Orelabrutinib: 150 mg/time, qd, po, D1-21

Trial Locations (2)

226005

RECRUITING

Affiliated hospital of Nantong University, Nantong

Unknown

NOT_YET_RECRUITING

Jiangsu Province Hospital, Nanjing

All Listed Sponsors
lead

Affiliated Hospital of Nantong University

OTHER